Job Trends
An investigational asthma treatment, tezepelumab, under development by Amgen and AstraZeneca failed to reduce asthma patients’ dependence on corticosteroids.
Labor Market Reports
BioSpace’s Q3 2025 U.S. Life Sciences Job Market Report reveals a turbulent quarter for biopharma hiring, with record declines in job postings, rising layoffs, and cautious employer sentiment shaping the industry’s employment landscape.
BioSpace data show biopharma professionals faced increased competition for fewer employment opportunities during the second quarter of 2025, with increased pressure from further layoffs.
Establishing trust through thought leadership is no longer optional in today’s cautious biopharma market. Learn how strategic insights and targeted outreach can turn awareness into high-converting leads.
Now Hiring
Looking for a biopharma job in New York? Check out the BioSpace list of eight companies hiring life sciences professionals like you.
Of the 25 companies receiving tax incentives in Massachusetts, 23 will add jobs outside of Boston and Cambridge. Medtronic, which is receiving the largest award, will create 220 roles in Billerica. Other recipients include AbbVie, Dyne Therapeutics and Viridian Therapeutics.
Looking for a job in regulatory? Check out the BioSpace list of eight companies hiring life sciences professionals like you.
THE LATEST
Amneal is planning an expansion of its New York facilities that will create hundreds of jobs as it and Impax Labs near completion of a planned merger.
Most investors and analysts are expecting 2018 to be a big year for mergers and acquisitions.
Sanofi has announced major restructuring, which will involve layoffs.
The deal has Sanofi paying $105 per share in cash.
The announcement sent shares of Juno soaring more than 27 percent in pre-market trading to $86.26.
Life sciences professionals don’t have to look far for opportunity in Genetown.
The survey of 51 oncologists suggests broad uptake of Imfinzi in advanced lung cancer patients who can’t be treated with surgery.
Astra has seen a fourfold increase in research productivity following a narrowing of disease focus and cuts in laboratory and staff over the past seven years, Reuters reported Thursday.
Shire will have its new CFO in March.
All of the recent problems have caused the company’s largest shareholder to push for a sale.